chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Age: 83.0
Sex: F
Vaccine: COVID19
Symptoms: Vaccination complication
Clinical narrative: fixed drug reaction; This spontaneous case was reported by a physician and describes the occurrence of VACCINATION COMPLICATION (fixed drug reaction) in an 83-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     Previously administered products included for an unreported indication: SHINGRIX.   On an unknown date, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient experienced VACCINATION COMPLICATION (fixed drug reaction). At the time of the report, VACCINATION COMPLICATION (fixed drug reaction) had not resolved. Not Provided      For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   Concomitant product use was unknown by the reporter. Treatment information was not provided. Reporter stated that he want to consider whether there were ingredients common to moderna covid and shigrix vaccinations so as to avoid further significant vaccine reactions.  The patient had fixed drug reaction at second vaccination site on deltoid. There was tumid, erythematous to violet and hyperpigmented large plaque on deltoid with distant lesions featuring hyperpigmentation present on arms. The patient stated that the adverse event was most likely caused by vaccine.   Most recent FOLLOW-UP information incorporated above includes: On 27-Jul-2021: Additional information received on 27-Jul-2021.Updated reporter information; added patient details and event details.
Age: 41.0
Sex: F
Vaccine: COVID19
Symptoms: Fatigue, Product availability issue
Clinical narrative: just tired; Caller is past the 35 day mark for the second dose / I was not able to get my 2nd dose; This spontaneous case was reported by a consumer and describes the occurrence of PRODUCT AVAILABILITY ISSUE (Caller is past the 35 day mark for the second dose / I was not able to get my 2nd dose) and FATIGUE (just tired) in a 41-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 007B21A) for COVID-19 vaccination.     No Medical History information was reported.    On 05-May-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 05-May-2021, the patient experienced PRODUCT AVAILABILITY ISSUE (Caller is past the 35 day mark for the second dose / I was not able to get my 2nd dose). On 06-May-2021, the patient experienced FATIGUE (just tired). On 10-May-2021, FATIGUE (just tired) had resolved. At the time of the report, PRODUCT AVAILABILITY ISSUE (Caller is past the 35 day mark for the second dose / I was not able to get my 2nd dose) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   no concomitants and treatments medications was reported.   Most recent FOLLOW-UP information incorporated above includes: On 15-Jul-2021: Translation received on 15 Jul 2021 and contain significant information. added patient demographics, added vaccine information, added event fatigue.
Age: 27.0
Sex: M
Vaccine: COVID19
Symptoms: SARS-CoV-2 test positive
Clinical narrative: tested positive for Covid-19; This spontaneous case was reported by a physician and describes the occurrence of SARS-COV-2 TEST POSITIVE (tested positive for Covid-19) in a 27-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 039K20A) for COVID-19 vaccination.     No medical history was provided by the reporter.     On 15-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 11-Jul-2021, the patient experienced SARS-COV-2 TEST POSITIVE (tested positive for Covid-19). On 11-Jul-2021, SARS-COV-2 TEST POSITIVE (tested positive for Covid-19) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   This case was linked to MOD-2021-257895 (Patient Link).
Age: 32.0
Sex: M
Vaccine: COVID19
Symptoms: Swelling of eyelid
Clinical narrative: Swollen Eyelids/ Swollen Eyelids happen frequently; This spontaneous case was reported by a consumer and describes the occurrence of SWELLING OF EYELID (Swollen Eyelids/ Swollen Eyelids happen frequently) in a 32-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 033C21A and 016C21A) for COVID-19 vaccination.     No Medical History information was reported.   On 22-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 24-May-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 22-Apr-2021, the patient experienced SWELLING OF EYELID (Swollen Eyelids/ Swollen Eyelids happen frequently). At the time of the report, SWELLING OF EYELID (Swollen Eyelids/ Swollen Eyelids happen frequently) outcome was unknown.            No concomitant medications were provided.   Treatment information included that physician instructed patient to take OTC Antihistamines, but patient has not taken any medicine.  The swollen eyelids happen frequently.   This case was linked to MOD-2021-257961 (Patient Link).
Age: 27.0
Sex: F
Vaccine: COVID19
Symptoms: Ageusia, Anosmia, Arthralgia, Body temperature, Cough
Clinical narrative: loss of smell; unanticipated cycle menstruation; lost of taste; sinusitis; cough; green sputum; myalgia; arthralgia; headache; extreme fatigue; low grade fever; This spontaneous case was reported by a physician and describes the occurrence of MYALGIA (myalgia), ARTHRALGIA (arthralgia), HEADACHE (headache), FATIGUE (extreme fatigue) and PYREXIA (low grade fever) in a 27-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 028L20A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     No medical history was provided by the reporter.  Concurrent medical conditions included Ulcerative colitis. Concomitant products included Remicade infusions for Ulcerative colitis.   On 15-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 12-Feb-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 15-Jan-2021, the patient experienced MYALGIA (myalgia), ARTHRALGIA (arthralgia), HEADACHE (headache), FATIGUE (extreme fatigue) and PYREXIA (low grade fever). On 08-Jul-2021, the patient experienced AGEUSIA (lost of taste), SINUSITIS (sinusitis), COUGH (cough) and PRODUCTIVE COUGH (green sputum). On an unknown date, the patient experienced ANOSMIA (loss of smell) and MENSTRUATION NORMAL (unanticipated cycle menstruation). On 17-Jan-2021, MYALGIA (myalgia), ARTHRALGIA (arthralgia), HEADACHE (headache), FATIGUE (extreme fatigue) and PYREXIA (low grade fever) had resolved. At the time of the report, AGEUSIA (lost of taste), ANOSMIA (loss of smell), SINUSITIS (sinusitis), COUGH (cough), PRODUCTIVE COUGH (green sputum) and MENSTRUATION NORMAL (unanticipated cycle menstruation) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On an unknown date, Body temperature: 103.5 °f High. On an unknown date, SARS-CoV-2 antibody test: positive (Inconclusive) Patient was tested via PCR (nasal swab) in the hospital..     For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   Treatment include monoclonal antibody therapy due to the severe Covid-19.  No treatment medications were provided.  Action taken with mRNA-1273 in response to the event was not applicable.   This case was linked to MOD-2021-257954 (Patient Link).
Age: 27.0
Sex: F
Vaccine: COVID19
Symptoms: Fatigue, Headache, Menstruation normal, Myalgia, Productive cough
Clinical narrative: loss of smell; unanticipated cycle menstruation; lost of taste; sinusitis; cough; green sputum; myalgia; arthralgia; headache; extreme fatigue; low grade fever; This spontaneous case was reported by a physician and describes the occurrence of MYALGIA (myalgia), ARTHRALGIA (arthralgia), HEADACHE (headache), FATIGUE (extreme fatigue) and PYREXIA (low grade fever) in a 27-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 028L20A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     No medical history was provided by the reporter.  Concurrent medical conditions included Ulcerative colitis. Concomitant products included Remicade infusions for Ulcerative colitis.   On 15-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 12-Feb-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 15-Jan-2021, the patient experienced MYALGIA (myalgia), ARTHRALGIA (arthralgia), HEADACHE (headache), FATIGUE (extreme fatigue) and PYREXIA (low grade fever). On 08-Jul-2021, the patient experienced AGEUSIA (lost of taste), SINUSITIS (sinusitis), COUGH (cough) and PRODUCTIVE COUGH (green sputum). On an unknown date, the patient experienced ANOSMIA (loss of smell) and MENSTRUATION NORMAL (unanticipated cycle menstruation). On 17-Jan-2021, MYALGIA (myalgia), ARTHRALGIA (arthralgia), HEADACHE (headache), FATIGUE (extreme fatigue) and PYREXIA (low grade fever) had resolved. At the time of the report, AGEUSIA (lost of taste), ANOSMIA (loss of smell), SINUSITIS (sinusitis), COUGH (cough), PRODUCTIVE COUGH (green sputum) and MENSTRUATION NORMAL (unanticipated cycle menstruation) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On an unknown date, Body temperature: 103.5 °f High. On an unknown date, SARS-CoV-2 antibody test: positive (Inconclusive) Patient was tested via PCR (nasal swab) in the hospital..     For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   Treatment include monoclonal antibody therapy due to the severe Covid-19.  No treatment medications were provided.  Action taken with mRNA-1273 in response to the event was not applicable.   This case was linked to MOD-2021-257954 (Patient Link).
Age: 27.0
Sex: F
Vaccine: COVID19
Symptoms: Pyrexia, SARS-CoV-2 antibody test, Sinusitis
Clinical narrative: loss of smell; unanticipated cycle menstruation; lost of taste; sinusitis; cough; green sputum; myalgia; arthralgia; headache; extreme fatigue; low grade fever; This spontaneous case was reported by a physician and describes the occurrence of MYALGIA (myalgia), ARTHRALGIA (arthralgia), HEADACHE (headache), FATIGUE (extreme fatigue) and PYREXIA (low grade fever) in a 27-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 028L20A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     No medical history was provided by the reporter.  Concurrent medical conditions included Ulcerative colitis. Concomitant products included Remicade infusions for Ulcerative colitis.   On 15-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 12-Feb-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 15-Jan-2021, the patient experienced MYALGIA (myalgia), ARTHRALGIA (arthralgia), HEADACHE (headache), FATIGUE (extreme fatigue) and PYREXIA (low grade fever). On 08-Jul-2021, the patient experienced AGEUSIA (lost of taste), SINUSITIS (sinusitis), COUGH (cough) and PRODUCTIVE COUGH (green sputum). On an unknown date, the patient experienced ANOSMIA (loss of smell) and MENSTRUATION NORMAL (unanticipated cycle menstruation). On 17-Jan-2021, MYALGIA (myalgia), ARTHRALGIA (arthralgia), HEADACHE (headache), FATIGUE (extreme fatigue) and PYREXIA (low grade fever) had resolved. At the time of the report, AGEUSIA (lost of taste), ANOSMIA (loss of smell), SINUSITIS (sinusitis), COUGH (cough), PRODUCTIVE COUGH (green sputum) and MENSTRUATION NORMAL (unanticipated cycle menstruation) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On an unknown date, Body temperature: 103.5 °f High. On an unknown date, SARS-CoV-2 antibody test: positive (Inconclusive) Patient was tested via PCR (nasal swab) in the hospital..     For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   Treatment include monoclonal antibody therapy due to the severe Covid-19.  No treatment medications were provided.  Action taken with mRNA-1273 in response to the event was not applicable.   This case was linked to MOD-2021-257954 (Patient Link).
Age: 73.0
Sex: F
Vaccine: COVID19
Symptoms: Balance disorder, Diplopia, Pain, Product dose omission issue, Urticaria
Clinical narrative: Raised localized reaction; lost some balance; Double vision; raised localized reaction that was very painful; welt; she has not had the second dose; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION COMPLICATION (Raised localized reaction), BALANCE DISORDER (lost some balance), DIPLOPIA (Double vision), PAIN (raised localized reaction that was very painful) and URTICARIA (welt) in a 73-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 030M20A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     No medical history was provided by the reporter.  Concomitant products included VITAMIN D NOS for an unknown indication.    On 11-Feb-2021 at 1:00 PM, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced VACCINATION COMPLICATION (Raised localized reaction), BALANCE DISORDER (lost some balance), DIPLOPIA (Double vision), PAIN (raised localized reaction that was very painful), URTICARIA (welt) and PRODUCT DOSE OMISSION ISSUE (she has not had the second dose). The patient was treated with PARACETAMOL (TYLENOL) on 12-Feb-2021 for Adverse event, at an unspecified dose and frequency. At the time of the report, VACCINATION COMPLICATION (Raised localized reaction), BALANCE DISORDER (lost some balance), DIPLOPIA (Double vision), PAIN (raised localized reaction that was very painful), URTICARIA (welt) and PRODUCT DOSE OMISSION ISSUE (she has not had the second dose) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   Most recent FOLLOW-UP information incorporated above includes: On 26-Jul-2021: Follow-up received on 26-JUL-2021 : Correspondence contact is Unchecked. Event outcome from Unknown to Recovered was updated.
Age: 73.0
Sex: F
Vaccine: COVID19
Symptoms: Vaccination complication
Clinical narrative: Raised localized reaction; lost some balance; Double vision; raised localized reaction that was very painful; welt; she has not had the second dose; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION COMPLICATION (Raised localized reaction), BALANCE DISORDER (lost some balance), DIPLOPIA (Double vision), PAIN (raised localized reaction that was very painful) and URTICARIA (welt) in a 73-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 030M20A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     No medical history was provided by the reporter.  Concomitant products included VITAMIN D NOS for an unknown indication.    On 11-Feb-2021 at 1:00 PM, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced VACCINATION COMPLICATION (Raised localized reaction), BALANCE DISORDER (lost some balance), DIPLOPIA (Double vision), PAIN (raised localized reaction that was very painful), URTICARIA (welt) and PRODUCT DOSE OMISSION ISSUE (she has not had the second dose). The patient was treated with PARACETAMOL (TYLENOL) on 12-Feb-2021 for Adverse event, at an unspecified dose and frequency. At the time of the report, VACCINATION COMPLICATION (Raised localized reaction), BALANCE DISORDER (lost some balance), DIPLOPIA (Double vision), PAIN (raised localized reaction that was very painful), URTICARIA (welt) and PRODUCT DOSE OMISSION ISSUE (she has not had the second dose) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   Most recent FOLLOW-UP information incorporated above includes: On 26-Jul-2021: Follow-up received on 26-JUL-2021 : Correspondence contact is Unchecked. Event outcome from Unknown to Recovered was updated.
Sex: F
Vaccine: COVID19
Symptoms: Expired product administered, Product storage error
Clinical narrative: patient was administered a vaccine that was left at room temprature for >12; left out past 12 hours and an expired dose administered/patient was administered a vaccine that was left at room temprature for >12; This spontaneous case was reported by a pharmacist and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (left out past 12 hours and an expired dose administered/patient was administered a vaccine that was left at room temprature for >12) and PRODUCT STORAGE ERROR (patient was administered a vaccine that was left at room temprature for >12) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 091B21A and 09021A) for COVID-19 vaccination.     No Medical History information was reported.   On 15-Jul-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 15-Jul-2021, the patient experienced EXPIRED PRODUCT ADMINISTERED (left out past 12 hours and an expired dose administered/patient was administered a vaccine that was left at room temprature for >12). On an unknown date, the patient experienced PRODUCT STORAGE ERROR (patient was administered a vaccine that was left at room temprature for >12). On 15-Jul-2021, EXPIRED PRODUCT ADMINISTERED (left out past 12 hours and an expired dose administered/patient was administered a vaccine that was left at room temprature for >12) had resolved. At the time of the report, PRODUCT STORAGE ERROR (patient was administered a vaccine that was left at room temprature for >12) had resolved.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   No relevant concomitant medications were reported.  No treatment information was provided.   Most recent FOLLOW-UP information incorporated above includes: On 03-Aug-2021: Follow-up received: Event added.
Age: 73.0
Sex: F
Vaccine: COVID19
Symptoms: Pain in extremity, Product dose omission issue, Pruritus
Clinical narrative: Past the 42 day mark; Left arm soreness; Itchiness; This spontaneous case was reported by a consumer and describes the occurrence of PRODUCT DOSE OMISSION ISSUE (Past the 42 day mark), PAIN IN EXTREMITY (Left arm soreness) and PRURITUS (Itchiness) in a 73-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 019B21A) for COVID-19 vaccination.     No medical history was provided by the reporter.  Concomitant products included THYROID (ARMOUR THYROID), LISINOPRIL, GLIPIZIDE and vitamins for an unknown indication.    On 17-May-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 17-May-2021, the patient experienced PRODUCT DOSE OMISSION ISSUE (Past the 42 day mark), PAIN IN EXTREMITY (Left arm soreness) and PRURITUS (Itchiness). At the time of the report, PRODUCT DOSE OMISSION ISSUE (Past the 42 day mark), PAIN IN EXTREMITY (Left arm soreness) and PRURITUS (Itchiness) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No treatment medications were taken.
Sex: M
Vaccine: COVID19
Symptoms: Asthenia, Dizziness
Clinical narrative: Dizziness; Weakness; This spontaneous case was reported by a consumer and describes the occurrence of DIZZINESS (Dizziness) and ASTHENIA (Weakness) in a male patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced DIZZINESS (Dizziness) and ASTHENIA (Weakness). At the time of the report, DIZZINESS (Dizziness) and ASTHENIA (Weakness) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No concomitant medication was reported. No treatment was reported.
Age: 38.0
Sex: M
Vaccine: COVID19
Symptoms: Incorrect product administration duration
Clinical narrative: first dose 60 days ago/ did not receive his second dose yet; This spontaneous case was reported by a consumer and describes the occurrence of INCORRECT PRODUCT ADMINISTRATION DURATION (first dose 60 days ago/ did not receive his second dose yet) in a 38-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 021C21A) for COVID-19 vaccination.     No Medical History information was reported.    On 13-May-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 13-May-2021, the patient experienced INCORRECT PRODUCT ADMINISTRATION DURATION (first dose 60 days ago/ did not receive his second dose yet). At the time of the report, INCORRECT PRODUCT ADMINISTRATION DURATION (first dose 60 days ago/ did not receive his second dose yet) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Concomitant product use was not provided by the reporter. No treatment information was provided. Consent given for safety to contact the patient and declined consent to contact his HCP
Age: 50.0
Sex: F
Vaccine: COVID19
Symptoms: Expired product administered
Clinical narrative: a dose administered from an expired Moderna COVID 19 vaccine; This spontaneous case was reported by a pharmacist and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (a dose administered from an expired Moderna COVID 19 vaccine) in a 50-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 078c21a) for COVID-19 vaccination.     No Medical History information was reported.   On 14-Jul-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 14-Jul-2021, the patient experienced EXPIRED PRODUCT ADMINISTERED (a dose administered from an expired Moderna COVID 19 vaccine). On 14-Jul-2021, EXPIRED PRODUCT ADMINISTERED (a dose administered from an expired Moderna COVID 19 vaccine) had resolved.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   Concomitant product use was not provided by the reporter.   Reportedly, the vial was punctured for more than 12 hours and was administered to one patient on 14Jul2021. The vial was punctured at 11:56am on 13Jul2021. The expired dose was administered at 6:54pm on14Jul2021.   Treatment information was not provided.
Sex: F
Vaccine: COVID19
Symptoms: Product dose omission issue
Clinical narrative: first dose > 35 days ago; This spontaneous case was reported by a pharmacist and describes the occurrence of PRODUCT DOSE OMISSION ISSUE (first dose > 35 days ago) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On 17-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 17-Apr-2021, the patient experienced PRODUCT DOSE OMISSION ISSUE (first dose > 35 days ago). On 17-Apr-2021, PRODUCT DOSE OMISSION ISSUE (first dose > 35 days ago) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No relevant concomitant medication was reported. The treatment information was not provided.
Age: 26.0
Sex: F
Vaccine: COVID19
Symptoms: Product dose omission issue
Clinical narrative: More than 3 months away from first dose and now scheduling the second dose; This spontaneous case was reported by a consumer and describes the occurrence of PRODUCT DOSE OMISSION ISSUE (More than 3 months away from first dose and now scheduling the second dose) in a 26-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 001B21A) for COVID-19 vaccination.     No Medical History information was reported.    On 11-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 15-Jul-2021, the patient experienced PRODUCT DOSE OMISSION ISSUE (More than 3 months away from first dose and now scheduling the second dose). On 15-Jul-2021, PRODUCT DOSE OMISSION ISSUE (More than 3 months away from first dose and now scheduling the second dose) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No relevant Concomitant Medications were reported.  No treatment information provided.   This case was linked to MOD-2021-257992 (Parent-Child Link).   See case MOD-2021-257992 for details regarding the child case.
Age: 82.0
Sex: M
Vaccine: COVID19
Symptoms: Hypoaesthesia, Insomnia, Pain in extremity, Paraesthesia
Clinical narrative: Difficulty sleeping on the side of left arm; Numb/ Continuous numbness; Tingling sensation/runs all the way down that arm to the fingertips/Continuous tingling; Pain in fingertips; This spontaneous case was reported by a consumer (subsequently medically confirmed) and describes the occurrence of INSOMNIA (Difficulty sleeping on the side of left arm), HYPOAESTHESIA (Numb/ Continuous numbness), PARAESTHESIA (Tingling sensation/runs all the way down that arm to the fingertips/Continuous tingling) and PAIN IN EXTREMITY (Pain in fingertips) in an 83-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 030A21A and 031L20A) for COVID-19 vaccination.     The patient's past medical history included Stroke. Concomitant products included APIXABAN (ELIQUIS) for an unknown indication.   On 04-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 01-Apr-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On an unknown date, the patient experienced INSOMNIA (Difficulty sleeping on the side of left arm), HYPOAESTHESIA (Numb/ Continuous numbness), PARAESTHESIA (Tingling sensation/runs all the way down that arm to the fingertips/Continuous tingling) and PAIN IN EXTREMITY (Pain in fingertips). At the time of the report, INSOMNIA (Difficulty sleeping on the side of left arm), HYPOAESTHESIA (Numb/ Continuous numbness), PARAESTHESIA (Tingling sensation/runs all the way down that arm to the fingertips/Continuous tingling) and PAIN IN EXTREMITY (Pain in fingertips) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   Treatment information was not provided.  Action taken with mRNA-1273 in response to the events was not applicable.
Age: 66.0
Sex: M
Vaccine: COVID19
Symptoms: Body temperature, Heart rate, Pyrexia
Clinical narrative: This spontaneous case reported by a consumer, describes the occurrence of pyrexia (temperature over 100 degrees for 24 hours) in a 66-year-old male patient who received mRNA-1273 (Moderna COVID-19 vaccine, batch/lot# 010A21A) for COVID-19  immunization. No medical history reported. On Feb 27, 2021, patient received the first dose of mRNA-1273 (Moderna COVID-19 vaccine), intramuscular; 1 dosage form. In June 2021, received second dose of mRNA-1273 (Moderna COVID-19 vaccine), unknown route; 1 dosage form. On an unknown date, patient experienced pyrexia (temperature over 100 degrees for 24 hours). At the time of the report, pyrexia (temperature over 100 degrees for 24 hours) outcome: unknown. Diagnostic results: On an unknown date, body temperature: 100 (high) temperature over 100 degrees for 24 hours. On an unknown date, heart rate: abnormal. Had fast heart rate. No concomitant medication or treatment information reported. The action taken with mRNA-1273 (Moderna COVID-19 vaccine) in response to the events: not applicable. This case linked to MOD-2021-251494 (patient link).
Age: 34.0
Sex: M
Vaccine: COVID19
Symptoms: Vaccination site erythema, Vaccination site swelling
Clinical narrative: Redness at injection site; swelling at injection site; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION SITE ERYTHEMA (Redness at injection site) and VACCINATION SITE SWELLING (swelling at injection site) in a 34-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 045C21A) for COVID-19 vaccination.     No medical history was provided by the reporter.  Concomitant products included LISINOPRIL for ACE inhibitor fetopathy.    On 07-Jul-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 08-Jul-2021, the patient experienced VACCINATION SITE ERYTHEMA (Redness at injection site) and VACCINATION SITE SWELLING (swelling at injection site). At the time of the report, VACCINATION SITE ERYTHEMA (Redness at injection site) and VACCINATION SITE SWELLING (swelling at injection site) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No treatment medications were provided
Sex: F
Vaccine: COVID19
Symptoms: Back pain, Product dose omission issue, Vaccination site pain, Vaccination site swelling
Clinical narrative: Pain in back still present; Swelling in the injection arm; Pain in injection arm subsided; Second dose not received; This spontaneous case was reported by a consumer and describes the occurrence of BACK PAIN (Pain in back still present), VACCINATION SITE SWELLING (Swelling in the injection arm), VACCINATION SITE PAIN (Pain in injection arm subsided  ) and PRODUCT DOSE OMISSION ISSUE (Second dose not received) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced BACK PAIN (Pain in back still present), VACCINATION SITE SWELLING (Swelling in the injection arm), VACCINATION SITE PAIN (Pain in injection arm subsided  ) and PRODUCT DOSE OMISSION ISSUE (Second dose not received). At the time of the report, BACK PAIN (Pain in back still present) had not resolved and VACCINATION SITE SWELLING (Swelling in the injection arm), VACCINATION SITE PAIN (Pain in injection arm subsided  ) and PRODUCT DOSE OMISSION ISSUE (Second dose not received) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       Concomitant product use was not provided by the reporter.   Reportedly, the patient did not receive the second dose at that time because she was still dealing with swelling in the injection arm and extreme back pain centering on the left lateral muscle.  In APR-2021, her doctor recommended that she was correct in not getting the second dose of the vaccine. The patient is not considering getting the second dose of the vaccine due to the Delta variant of the virus. Recently, the patient received a call from her doctor's office recommending that she do receive the second dose.   Treatment information was not provided.
Age: 48.0
Sex: F
Vaccine: COVID19
Symptoms: Hypersensitivity, Intentional product use issue, Rash, Vaccination complication
Clinical narrative: First dose of Moderna vaccine in March2021 and had a reaction to it; Localized reaction; Not going to get the second dose but recently decided they may want to, receive her second dose; rash; This spontaneous case was reported by a pharmacist and describes the occurrence of VACCINATION COMPLICATION (First dose of Moderna vaccine in March2021 and had a reaction to it), HYPERSENSITIVITY (Localized reaction), INTENTIONAL PRODUCT USE ISSUE (Not going to get the second dose but recently decided they may want to, receive her second dose) and RASH (rash) in a 48-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 039C21A) for COVID-19 vaccination.     No Medical History information was reported.   In March 2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 22-Jul-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to at an unspecified dose. On an unknown date, the patient experienced VACCINATION COMPLICATION (First dose of Moderna vaccine in March2021 and had a reaction to it), HYPERSENSITIVITY (Localized reaction), INTENTIONAL PRODUCT USE ISSUE (Not going to get the second dose but recently decided they may want to, receive her second dose) and RASH (rash). At the time of the report, VACCINATION COMPLICATION (First dose of Moderna vaccine in March2021 and had a reaction to it) and INTENTIONAL PRODUCT USE ISSUE (Not going to get the second dose but recently decided they may want to, receive her second dose) outcome was unknown and HYPERSENSITIVITY (Localized reaction) and RASH (rash) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) and mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   Concomitant product use was not provided by the reporter.  Treatment information was not provided. Patient went to her physician and was cleared to receive the second dose.   Most recent FOLLOW-UP information incorporated above includes: On 24-Jul-2021: Follow up received and contains no new information. On 27-Jul-2021: Follow up received- Dose-2 information start date batch number/pt demographics update
Age: 34.0
Sex: F
Vaccine: COVID19
Symptoms: Arthralgia, Bone pain, Fatigue, Feeling abnormal, Myalgia
Clinical narrative: She felt horrible for 5 days; She had bone pain; She had body aches/everything hurt; She had joint pain; She was really tired; This spontaneous case was reported by a consumer and describes the occurrence of FEELING ABNORMAL (She felt horrible for 5 days), BONE PAIN (She had bone pain), MYALGIA (She had body aches/everything hurt), ARTHRALGIA (She had joint pain) and FATIGUE (She was really tired) in a 34-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 007C21A and 038C21A) for COVID-19 vaccination.     No medical history was provided by the reporter.  Concomitant products included AMFETAMINE ASPARTATE, AMFETAMINE SULFATE, DEXAMFETAMINE SACCHARATE, DEXAMFETAMINE SULFATE (ADDERALL) and DULOXETINA [DULOXETINE] for an unknown indication.   On 01-May-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 01-Jun-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to at an unspecified dose. On 01-May-2021, the patient experienced FEELING ABNORMAL (She felt horrible for 5 days), BONE PAIN (She had bone pain), MYALGIA (She had body aches/everything hurt), ARTHRALGIA (She had joint pain) and FATIGUE (She was really tired). The patient was treated with IBUPROFEN at an unspecified dose and frequency. On 06-May-2021, FEELING ABNORMAL (She felt horrible for 5 days), BONE PAIN (She had bone pain), MYALGIA (She had body aches/everything hurt), ARTHRALGIA (She had joint pain) and FATIGUE (She was really tired) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) and mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   This case was linked to MOD-2021-258011 (Patient Link).
Age: 52.0
Sex: M
Vaccine: COVID19
Symptoms: Pain, Vaccination site scab
Clinical narrative: Scabbing at the injection site/the scab grows bigger and bigger and then falls off; Painful; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION SITE SCAB (Scabbing at the injection site/the scab grows bigger and bigger and then falls off), PAIN (Painful) and HAEMORRHAGE (it bleeds a little both then grows) in a 52-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 022C21A) for COVID-19 vaccination.     Concurrent medical conditions included Diabetes. Concomitant products included INSULIN GLARGINE (SEMGLEE), AMYLIN [AMLINTIDE], LISINOPRIL and ESCITALOPRAM OXALATE (LEXAPRO) for an unknown indication.   On 05-May-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced VACCINATION SITE SCAB (Scabbing at the injection site/the scab grows bigger and bigger and then falls off), PAIN (Painful) and HAEMORRHAGE (it bleeds a little both then grows). At the time of the report, VACCINATION SITE SCAB (Scabbing at the injection site/the scab grows bigger and bigger and then falls off), PAIN (Painful) and HAEMORRHAGE (it bleeds a little both then grows) had not resolved.            The action taken with mRNA-1273 in response to the events were not applicable.  No treatment medication was provided.   Most recent FOLLOW-UP information incorporated above includes: On 30-Jul-2021: reporter declined for further follow up
Age: 62.0
Sex: F
Vaccine: COVID19
Symptoms: Fatigue, Headache, Hypersensitivity, Myalgia, Nasopharyngitis
Clinical narrative: "felt like has cold"; increase in daily allergies; fatigue; Headache; sore arm; This spontaneous case was reported by a consumer and describes the occurrence of NASOPHARYNGITIS ("felt like has cold"), HYPERSENSITIVITY (increase in daily allergies), FATIGUE (fatigue), HEADACHE (Headache) and MYALGIA (sore arm) in a 62-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 006M20A) for COVID-19 vaccination.     Concurrent medical conditions included Blood pressure high and Allergy. Concomitant products included IBUPROFEN, DIPHENHYDRAMINE HYDROCHLORIDE (BENADRYL [DIPHENHYDRAMINE HYDROCHLORIDE]), BUPROPION HYDROCHLORIDE (WELLBUTRIN), FLUOXETINE HYDROCHLORIDE (PROZAC) and BENZONATATE (TESSALON) for an unknown indication.    On 11-May-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 11-May-2021, the patient experienced MYALGIA (sore arm). On an unknown date, the patient experienced NASOPHARYNGITIS ("felt like has cold"), HYPERSENSITIVITY (increase in daily allergies), FATIGUE (fatigue) and HEADACHE (Headache). On 15-May-2021, MYALGIA (sore arm) had resolved. At the time of the report, NASOPHARYNGITIS ("felt like has cold"), HYPERSENSITIVITY (increase in daily allergies), FATIGUE (fatigue) and HEADACHE (Headache) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Concomitant drug included high blood pressure pills. Treatment medication was not reported.   This case was linked to MOD-2021-229486 (Patient Link).
Sex: U
Vaccine: COVID19
Symptoms: COVID-19, Illness
Clinical narrative: still sick with midl symptoms; got Covid last week; This spontaneous case was reported by a patient and describes the occurrence of COVID-19 (got Covid last week) and ILLNESS (still sick with midl symptoms) in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. In July 2021, the patient experienced COVID-19 (got Covid last week). On an unknown date, the patient experienced ILLNESS (still sick with midl symptoms). At the time of the report, COVID-19 (got Covid last week) and ILLNESS (still sick with midl symptoms) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No concomitant medications was reported. No treatment drug details was reported.
Age: 34.0
Sex: F
Vaccine: COVID19
Symptoms: Dizziness, Fatigue, Injection site hypoaesthesia, Injection site rash, Myalgia
Clinical narrative: Numbess at injection site; Large red welt at injection site; Soreness at the injection site; Fatigue; Muscle aches; Body/Joint/bone aches; Dizzy; This spontaneous case was reported by a consumer and describes the occurrence of PAIN IN EXTREMITY (Body/Joint/bone aches), DIZZINESS (Dizzy), INJECTION SITE HYPOAESTHESIA (Numbess at injection site), INJECTION SITE RASH (Large red welt at injection site) and VACCINATION SITE PAIN (Soreness at the injection site) in a 34-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 038C21A and 007C21A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     Concurrent medical conditions included Ulcerative colitis (Improvement has been observed) since 01-Jun-2009. Concomitant products included AMFETAMINE ASPARTATE, AMFETAMINE SULFATE, DEXAMFETAMINE SACCHARATE, DEXAMFETAMINE SULFATE (ADDERALL) from 01-Jun-2021 to an unknown date for ADHD, DULOXETINE HYDROCHLORIDE (DULOXETINA ALTER) from 30-Apr-2021 to an unknown date for Depression.   On 01-May-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 01-Jun-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 02-Jun-2021, the patient experienced PAIN IN EXTREMITY (Body/Joint/bone aches), DIZZINESS (Dizzy), INJECTION SITE RASH (Large red welt at injection site), VACCINATION SITE PAIN (Soreness at the injection site), FATIGUE (Fatigue) and MYALGIA (Muscle aches). On 22-Jun-2021, the patient experienced INJECTION SITE HYPOAESTHESIA (Numbess at injection site). On 09-Jun-2021, PAIN IN EXTREMITY (Body/Joint/bone aches), DIZZINESS (Dizzy), FATIGUE (Fatigue) and MYALGIA (Muscle aches) had resolved. On 16-Jun-2021, INJECTION SITE RASH (Large red welt at injection site) and VACCINATION SITE PAIN (Soreness at the injection site) had resolved. At the time of the report, INJECTION SITE HYPOAESTHESIA (Numbess at injection site) had not resolved.            No treatment information was provided   This case was linked to MOD-2021-258005 (Patient Link).   Most recent FOLLOW-UP information incorporated above includes: On 28-Jul-2021: Reporter information, demographic details, race and ethnicity were updated. Medical history ,dose information, concomitant medications were added. New events were added.
Age: 34.0
Sex: F
Vaccine: COVID19
Symptoms: Pain in extremity, Vaccination site pain
Clinical narrative: Numbess at injection site; Large red welt at injection site; Soreness at the injection site; Fatigue; Muscle aches; Body/Joint/bone aches; Dizzy; This spontaneous case was reported by a consumer and describes the occurrence of PAIN IN EXTREMITY (Body/Joint/bone aches), DIZZINESS (Dizzy), INJECTION SITE HYPOAESTHESIA (Numbess at injection site), INJECTION SITE RASH (Large red welt at injection site) and VACCINATION SITE PAIN (Soreness at the injection site) in a 34-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 038C21A and 007C21A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     Concurrent medical conditions included Ulcerative colitis (Improvement has been observed) since 01-Jun-2009. Concomitant products included AMFETAMINE ASPARTATE, AMFETAMINE SULFATE, DEXAMFETAMINE SACCHARATE, DEXAMFETAMINE SULFATE (ADDERALL) from 01-Jun-2021 to an unknown date for ADHD, DULOXETINE HYDROCHLORIDE (DULOXETINA ALTER) from 30-Apr-2021 to an unknown date for Depression.   On 01-May-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 01-Jun-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 02-Jun-2021, the patient experienced PAIN IN EXTREMITY (Body/Joint/bone aches), DIZZINESS (Dizzy), INJECTION SITE RASH (Large red welt at injection site), VACCINATION SITE PAIN (Soreness at the injection site), FATIGUE (Fatigue) and MYALGIA (Muscle aches). On 22-Jun-2021, the patient experienced INJECTION SITE HYPOAESTHESIA (Numbess at injection site). On 09-Jun-2021, PAIN IN EXTREMITY (Body/Joint/bone aches), DIZZINESS (Dizzy), FATIGUE (Fatigue) and MYALGIA (Muscle aches) had resolved. On 16-Jun-2021, INJECTION SITE RASH (Large red welt at injection site) and VACCINATION SITE PAIN (Soreness at the injection site) had resolved. At the time of the report, INJECTION SITE HYPOAESTHESIA (Numbess at injection site) had not resolved.            No treatment information was provided   This case was linked to MOD-2021-258005 (Patient Link).   Most recent FOLLOW-UP information incorporated above includes: On 28-Jul-2021: Reporter information, demographic details, race and ethnicity were updated. Medical history ,dose information, concomitant medications were added. New events were added.
Sex: F
Vaccine: COVID19
Symptoms: Pain
Clinical narrative: The 2nd shot I had a little more pain fit maybe 2 days / very little pain /alittle extra soreness for a day or two.; This spontaneous case was reported by a consumer and describes the occurrence of PAIN (The 2nd shot I had a little more pain fit maybe 2 days / very little pain /alittle extra soreness for a day or two.) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     The patient's past medical history included Hemorrhage and Pancreaticoduodenectomy (pancreatic surgery). Concurrent medical conditions included Cancer, Reflex sympathetic dystrophy and Nerve damage (Blood clots).    On an unknown date, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced PAIN (The 2nd shot I had a little more pain fit maybe 2 days / very little pain /alittle extra soreness for a day or two.). At the time of the report, PAIN (The 2nd shot I had a little more pain fit maybe 2 days / very little pain /alittle extra soreness for a day or two.) outcome was unknown.            No relevant concomitant medications were reported.  No treatment information was provided.   This case was linked to MOD-2021-060668 (Patient Link).   Most recent FOLLOW-UP information incorporated above includes: On 17-Jul-2021: Follow up received on 17-JUL-2021, included Patient relevant history was added. On 02-Aug-2021: Follow-up received: Non-significant information.